{"id":2344,"date":"2016-03-07T03:14:18","date_gmt":"2016-03-07T08:14:18","guid":{"rendered":"http:\/\/allphasepharma.com\/dir\/?p=2344"},"modified":"2016-03-23T04:39:07","modified_gmt":"2016-03-23T08:39:07","slug":"recent-sepsis-literature","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2016\/03\/07\/2344\/recent-sepsis-literature\/","title":{"rendered":"Recent Sepsis Literature"},"content":{"rendered":"

\"Sepsis<\/a><\/p>\n

SIRS, sepsis, severe sepsis, septic shock is a continuum, a crescendo of signs and symptoms associated with an infection uncontrolled by host responses. An avalanche or cascade of seemingly unstoppable events occurs often in a matter of hours which has defied causal intervention but for which symptomatic treatment has improved the outcomes over the years, significantly reducing mortality.<\/p>\n

This time-honored classification, introduced in the early 90s by Roger Bone et al [1]<\/a>,\u00a0created\u00a0artificial separation lines in a process which has no distinctive qualitative steps. But lacking better alternatives we stick with what we have: after all, there seemed to be\u00a0a step-wise increase in mortality based on the number of SIRS criteria in earlier epidemiologic studies.<\/p>\n

While this\u00a0classification scheme was of\u00a0some use in\u00a0academic discussions, it certainly has not done well in the clinical arena. Not a single sepsis trial has shown efficacy in confirmatory trials.\u00a0In particular, mortality rates were not reproducible\u00a0on repeat testing in patient populations selected with great care despite\u00a0identical\u00a0sepsis definitions.

It is time to put the Bone criteria where they belong … the cemetery<\/strong><\/span>.<\/strong>\u00a0The concept just has not held up<\/span><\/strong><\/p>\n<\/div><\/p>\n

Sadly, the list of failed sepsis drugs is a very long one: It all started with\u00a0HA-1A, then came E5, the anti-TNF mAbs, Xigris, tifacogin, steroids, up to\u00a0the latest disappointment, E5564 (eritoran) from Eisai.<\/p>\n

\"Sepsis<\/a><\/p>\n

All were tested in the more advanced sepsis categories using the staging originally defined by Bone et al.\u00a0 All were well-designed large trials; the argument that some were underpowered is not the issue here.<\/p>\n

Alas, they all failed for one reason or another. We can blame the drugs for a lack of efficacy but it may well be that the\u00a0entity called \u2018sepsis\u2019 or sepsis syndrome\u2019 was not defining a succinct clinical and pathophysiological entity. It seems more that we were developing precision medicines for an imprecisely defined condition, or a spectrum of conditions. It is reminiscent of the shotgun approach to treating any infection with antibacterials even when viruses are the culprit for most cases.\u00a0

We need better diagnostic criteria and should abandon the SIRS \/ sepsis \/ severe sepsis mantra<\/strong><\/span><\/p>\n<\/div><\/p>\n

A recent publication by Kaukonen provides further arguments that some components of the severe sepsis definitions are not prognostically meaningful\u00a0[2]<\/a>. Contrary to earlier data, the presence of 2 or more SIRS criteria did not result in worse outcomes than the presence of only 1-2.\u00a0 Okay, nice to know but fairly irrelevant in the bigger scheme of things. No doubt, the next committee will dutifully adjust the severe sepsis criteria based on this insight. The change is unlikely to affect the conduct of studies for antibiotics or blockers of the inflammatory cascade.<\/p>\n

Too much in the sepsis vocabulary has become game of semantics: when do you call a brook a creek, and when does\u00a0a river become a\u00a0stream? Does it really matter and advance the field? It feels like moving gravestones around in the cemetery, to paraphrase the old adage.<\/p>\n

On a positive note, it is good to see how mortality in severe sepsis has been reduced\u00a0and almost cut in\u00a0half in the ICU over the years with symptomatic supportive interventions alone. A big \u201cThank you\u201d to our intensivist colleagues is in order.<\/p>\n

 <\/p>\n

References:<\/strong><\/p>\n

[1]<\/a> R Bone. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP\/SCCM Consensus Conference Committee. American College of Chest Physicians\/Society of Critical Care Medicine. Chest. 1992 Jun;101(6):1644<\/p>\n

[2]<\/a> K Kaukonen. Systemic Inflammatory Response Syndrome Criteria in Defining Severe Sepsis. N Engl J Med 2015;372:1629<\/p>\n

[3]<\/a> L Napoletano. Sepsis and the Syndrome of Multiple Organ Failure. In: Modern Surgical Care: Physiologic Foundations and Clinical Applications. Ed. T. Miller, CRC Press 2006 –\u00a0very good review of all aspects of sepsis and review of the older sepsis studies.<\/span><\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

SIRS, sepsis, severe sepsis, septic shock is a continuum, a crescendo of signs and symptoms associated with an infection uncontrolled by host responses. An avalanche or cascade of seemingly unstoppable events occurs often in a matter of hours which has defied causal intervention but for which symptomatic treatment has improved Continue reading Recent Sepsis Literature<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":2355,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[227,3,18],"tags":[1565,1271,1567,1566,1558,403,220,1553,1561,175,682,1555,689,687,1563,1583,1557,1559,1562,174,184,262,679,680,1554,1552,1556,692,1564,703,681,683,1560],"class_list":["post-2344","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recent_literature","category-the_news","category-the_viewpoint","tag-afelimomab","tag-allphase-pharma-consulting","tag-anti-il-1","tag-anti-paf","tag-anti-tnf-mab","tag-antibiotic-blog","tag-bayer","tag-bone-criteria","tag-centocor","tag-chiron","tag-drotrecogin","tag-e5","tag-eisai","tag-endotoxin","tag-ha-1a","tag-harald-reinhart","tag-icu-mortality","tag-ipsen","tag-map-195","tag-novartis","tag-roche","tag-sepsis","tag-sepsis-syndrome","tag-septic-shock","tag-severe-sepsis","tag-sirs","tag-sirs-criteria","tag-steroids","tag-synergen","tag-tfpi","tag-tifacogin","tag-xigris","tag-xoma"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/03\/Sepsis-slider-copy.jpg?fit=640%2C180&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-BO","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":1140,"url":"https:\/\/allphasepharma.com\/dir\/2014\/11\/17\/1140\/two-new-approaches-for-dealing-with-sepsis-toxemia\/","url_meta":{"origin":2344,"position":0},"title":"Two New Approaches For Dealing with Sepsis \/ Toxemia","author":"Harald","date":"November 17, 2014","format":false,"excerpt":"There is hardly an indication which has accumulated more failed clinical trials than the sepsis area.\u00a0 Called first bacteremia, later sepsis, sepsis syndrome or septic shock, there have been numerous attempts to influence the cascade of events that eventually lead to MSOF and death.\u00a0 While it is convenient to think\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/11\/sepsis-slider.jpg?fit=640%2C200&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/11\/sepsis-slider.jpg?fit=640%2C200&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/11\/sepsis-slider.jpg?fit=640%2C200&ssl=1&resize=525%2C300 1.5x"},"classes":[]},{"id":521,"url":"https:\/\/allphasepharma.com\/dir\/2014\/07\/06\/521\/aeromonas-salmonicida-trouble-for-aquaculture-with-drug-resistance\/","url_meta":{"origin":2344,"position":1},"title":"Aeromonas salmonicida: Trouble for Aquaculture with Drug Resistance","author":"Harald","date":"July 6, 2014","format":false,"excerpt":"Aeromonas salmonicida causes furunculosis in salmon hatcheries and in freshwater fish.\u00a0 The organism has several recognized virulence mechanisms including the T3SS\u00a0[1].\u00a0 A. salmonicida\u00a0has become resistant to penicillin, tetracycline and erythromycin.\u00a0 It remains susceptible to chloramphenicol and aminoglycoside according to a publication from Romania [2] but another reference describes it as\u2026","rel":"","context":"In "Did you know...?"","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"Salmon","src":"http:\/\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/07\/Salmon.jpe","width":350,"height":200},"classes":[]},{"id":6432,"url":"https:\/\/allphasepharma.com\/dir\/2026\/02\/25\/6432\/the-new-default-1-one-single-pivotal-trial\/","url_meta":{"origin":2344,"position":2},"title":"The New Default: 1 (One) Single Pivotal Trial","author":"Harald","date":"February 25, 2026","format":false,"excerpt":"Statements that have the words \u2018FDA\u2019 and \u2018flexibility\u2019 in a single sentence need to be approached with some skepticism.\u00a0 Especially if made by the Agency. \u2018Flexibility\u2019 always sounds better than \u2018less rigidity\u2019. Regulators are tasked with providing a certain sense of consistency or stability in the drug development jungle where\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/02\/slot-machines-winning-three-FDA-e1771883436805.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/02\/slot-machines-winning-three-FDA-e1771883436805.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/02\/slot-machines-winning-three-FDA-e1771883436805.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":1869,"url":"https:\/\/allphasepharma.com\/dir\/2015\/08\/19\/1869\/most-anti-infective-guidelines-get-no-respect-let-alone-use\/","url_meta":{"origin":2344,"position":3},"title":"Most Anti-Infective Guidelines Don’t Get No Respect (Let Alone Use!)","author":"Harald","date":"August 19, 2015","format":false,"excerpt":"It is no secret that most existing antibiotic guidelines are not getting much use these days.\u00a0 The only indications pursued with any regularity are the feasible ones: ABSSSI, cUTI, and cIAI, much less CABP.\u00a0 Yes, the occasional HABP\/VABP trial is being undertaken by the intrepid but no company has taken\u2026","rel":"","context":"In "Did you know...?"","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"indications - slider","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/indications-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/indications-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/indications-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":586,"url":"https:\/\/allphasepharma.com\/dir\/2014\/07\/13\/586\/penicillin-historical-tidbits\/","url_meta":{"origin":2344,"position":4},"title":"Penicillin – Historical Tidbits","author":"Harald","date":"July 13, 2014","format":false,"excerpt":"Publication of transatlantic efforts on penicillin purification and production was embargoed by the British and US governments during WWII? US companies were allowed to collaborate and share scientific information specifically to improve methods of penicillin production and were exempted from anti-trust laws which would have forbidden such anti-competitive behavior? the\u03b2-lactam\u2026","rel":"","context":"In "Did you know...?"","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"Penicillin mold","src":"http:\/\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/07\/Penicillin-mold.jpe","width":350,"height":200},"classes":[]},{"id":2061,"url":"https:\/\/allphasepharma.com\/dir\/2015\/10\/20\/2061\/polyphor-pol7080-and-the-journey-to-the-land-of-pyocyanea-part-2\/","url_meta":{"origin":2344,"position":5},"title":"Polyphor POL7080 And The Journey to The Land of Pyocyanea\u00a0 (Part 2)","author":"Harald","date":"October 20, 2015","format":false,"excerpt":"Roche\u2019s current Phase 2 program is strangely ambiguous. RG-7929 has not made it into www.clinicaltrials.gov yet, only POL7080 is listed. An uncontrolled open label study in \u201cpatients with non-CF acute exacerbation of bronchiectasis due to P. aeruginosa requiring IV treatment\u201d is enrolling. Well, good luck finding those patients! At best,\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"bridge Pyocyanea-P2","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/10\/bridge-Pyocyanea-P2.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/10\/bridge-Pyocyanea-P2.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/10\/bridge-Pyocyanea-P2.jpg?resize=525%2C300 1.5x"},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/2344","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=2344"}],"version-history":[{"count":11,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/2344\/revisions"}],"predecessor-version":[{"id":2365,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/2344\/revisions\/2365"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/2355"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=2344"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=2344"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=2344"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}